Interleukin‐6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression

Abstract

These studies suggest that acquisition of endogenous IL-6 production after prolong exposure of prostate cancer cells to IL-6 may contribute to an autocrine cell growth stimulation. Furthermore, the transition of IL-6 from a paracrine growth inhibitor to an autocrine growth stimulator suggests that IL-6 plays an important role during prostate cancer progression, possibly androgen-independent progression.